Organoid Culture Metabolite Control Patents: Who Leads 2026
- One filer dominates. the leading assignee holds 37 of the 92 records in scope, and the top 5 combined account for 75.0% of all filings.
- Filing peaked in 2021 at 26 records and fell to 3 by 2024, an 88% drop over that three-year span — though 2025-26 counts are still filling in due to publication lag.
- Dairy-product claims sit inside a cell-biology field. A23C dairy composition classes cover 25.0% of records, alongside C12M bioreactor claims at 20.7%, pointing to cultured-milk platforms as a real commercial thread.
Filing growth compares 2021 (26 records) with 2024 (3) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 92 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks patent filings at the intersection of three-dimensional organoid and organotypic culture and the metabolic control problems that determine whether a culture stays viable at scale: lactate accumulation, ammonia build-up, glucose and glutamine uptake, pH regulation and redox state. The scope is drawn from 92 published records filed between 2015 and mid-2026, classified under core cell-culture and bioreactor IPC codes (C12N5/071, C12N5/00, C12M3/00).
The dataset is small relative to broader biotech fields, which makes the concentration at the top more informative than the raw count: a handful of assignees have effectively defined the claim space so far, and the technology composition shows the field splitting between therapeutic organoid work and food-grade cultured-product platforms.
Filing trend and technology composition
Annual filing counts and IPC class shares for the 92 records in scope, drawn directly from the underlying dataset.
Filings rose sharply through 2021, then declined
Filings climbed from 11 in 2017 to a peak of 26 in 2021, then fell to 3 by 2024 — an 88% drop over that three-year span. Counts for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so the apparent decline should not be read as the field cooling; it is a data-lag artefact until later years catch up.
C12N dominates; dairy and bioreactor classes mark a commercial split
C12N (microorganisms and genetic engineering) appears on 98.9% of the 92 records, which is expected given the search scope. Below that, C07K peptide/protein claims (32.6%) and A61K medicinal preparation claims (30.4%) mark the therapeutic organoid branch, while A23C dairy product claims (25.0%) and C12M bioreactor apparatus claims (20.7%) mark a distinct cultured-food branch. Both branches are competing for the same underlying metabolite-control claim space.
Shares are the percentage of the 92 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Organoid Culture Metabolite Control with Eureka
This page is one run against one query. Ask Eureka your own question about organoid culture metabolite control and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative filing
EP2764099A1 — ECM composition, tumor microenvironment platform and methods thereof
The disclosure covers an Extra Cellular Matrix composition specific to cancer type and a tumor microenvironment platform for long-term culturing of tumor tissue, designed to mimic physiologically relevant signalling systems using human ligands and tumor tissue microenvironment. It further covers a Clinical Response Predictor used for treatment selection and for translational biology work such as anticancer drug development, plus a method for predicting a tumor patient's clinical response to specific drugs.Filed by Mitra RxDx India, 2014-08-13 — one of the earlier filings anchoring the therapeutic-organoid branch of this landscape.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2021242866A1 | Milk product compositions | 42 |
| 2 | WO2021141762A1 | Live cell constructs for production of cultured milk product and methods using the same | 37 |
| 3 | WO2013050962A1 | ECM composition, tumor microenvironment platform and methods thereof | 21 |
| 4 | US20210207090A1 | Live cell constructs for production of cultured milk product and methods using the same | 9 |
| 5 | US11111477B2 | Live cell constructs for production of cultured milk product and methods using the same | 6 |
| 6 | US20190352598A1 | Human plasma-like medium | 5 |
| 7 | EP3848454A1 | Live cell constructs for production of cultured milk product and methods using the same | 4 |
| 8 | US12270016B1 | Structure and function of modular microfluidic device for in-vitro modeling of human organs | 3 |
| 9 | WO2023026047A1 | Transmembrane device | 3 |
| 10 | US20210403865A1 | Live cell constructs for production of cultured milk product and methods using the same | 3 |
Citation counts favour older records within the searched corpus and should be read as a signal of influence, not current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing pattern tells you
Three findings that shape how a freedom-to-operate or whitespace review should be scoped in this field.
Filing sits with a small leader group, not a long tail
The top 5 assignees combined hold 75.0% of all 92 records in scope, and the top 10 extend that to 89.1%. With the leader alone at 37 records, any competitive read of this field has to start with what that single assignee's claims actually cover before assuming open ground exists.
The 2021 peak has not been sustained through complete-year data
Filings ran from 11 in 2017 up to 26 in 2021, then dropped to 3 by 2024, an 88% decline over that span. Because publication lags filing by roughly 18 months, 2025-26 figures are not yet reliable evidence of a further slowdown — treat 2024 as the last complete data point.
A cultured-food branch runs alongside the therapeutic-organoid branch
Beyond the near-universal C12N cell-culture classification, A23C dairy composition claims cover a quarter of records and C12M bioreactor apparatus claims cover 20.7% — evidence that metabolite-control techniques developed for organoid research are being claimed directly against cultured-milk and cultured-food production.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to organoid culture metabolite control, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| BIOMILQ INC | GUILIANO SHAYNE | 2 |
| MITRA BIOTECH | THIAGARAJAN SARAVANAN | 1 |
| MITRA BIOTECH | SUNDARAM MALLIKARJUN | 1 |
| MITRA BIOTECH | RADHAKRISHNAN PADHMA | 1 |
| MITRA BIOTECH | PINTO DENCY | 1 |
| MITRA BIOTECH | MAJUMDER PRADIP | 1 |
| MITRA BIOTECH | MAJUMDER BISWANATH | 1 |
| MITRA BIOTECH | JAIN MISTI | 1 |
Only 8 co-assignee pairs appear across the dataset, and the strongest pairs link a single company to individually named inventors rather than to other institutions — most of the claim space here was built by assignees filing alone.
Who holds the claim space
The assignee ranking covers 29 companies across the 92 records in scope. It is not a top-50 or top-100 cut — it is the complete ranking the dataset returns, and the leader alone accounts for 37 of those records.
One assignee anchors the cultured-food branch
The leading assignee's 37 records make it the single largest holder in this landscape by a wide margin over the next four combined competitors, concentrated around cultured-milk product compositions and the live-cell constructs used to produce them.
A mid-tier group holds single-digit record counts each
Past the leader, filing counts drop quickly — fifth place holds 6 records and tenth place holds 2 — which means most of the ranked assignees are defending narrow, specific claim territory rather than broad platform patents.
Nineteen assignees hold the remaining 10.9% of records
Academic and research-institute filers make up much of this group, filing individually rather than in the multi-party consortia seen in more mature fields — co-assignee pairs number only 8 across the whole dataset.
| Assignee | Recent year | YoY |
|---|---|---|
| BIOMILQ INC | 0 | -100% |
| MITRA RXDX INDIA PTE LTD | 0 | — |
| University of Chicago | 0 | — |
| Whitehead Institute for Biomedical Research | 0 | — |
| ADVANCED SOLUTIONS LIFE SCIENCES LLC | 0 | — |
| MITRA BIOTECH | 0 | — |
| Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | 0 | — |
| Cambridge Enterprise Ltd | 0 | — |
Where to take this
The concentration at the top and the incomplete recent-year data both point toward the same next step: a closer read of what the leading claims actually block.
Map the leader's claim boundaries
With one assignee holding 37 of 92 records, a freedom-to-operate check should start by reading that portfolio's independent claims before assuming any adjacent ground is open.
Run a claim comparison in Eureka →Watch the 2025-26 filings as they publish
Because publication lags filing by roughly 18 months, the true trend past 2024 is still forming; revisit the filing chart once later years complete.
Set a monitoring alert in Eureka →Test the under-claimed branches
Sub-areas like redox-state sensing and continuous-flow lactate control show thin coverage relative to the core field — worth a targeted search before drafting.
Explore white space in Eureka →Common questions about this landscape
One assignee leads with 37 of the 92 records in scope, well ahead of the rest of the ranked field. The top 5 assignees combined hold 75.0% of all records, and the top 10 hold 89.1%, so the field is concentrated rather than fragmented. That leader's portfolio centres on cultured-milk product compositions and the live-cell constructs used to produce them, which is a food-technology application of organoid metabolic control rather than a purely therapeutic one.
Filings rose from 11 in 2017 to a peak of 26 in 2021, then fell to 3 by 2024 — an 88% decline over that span, using the last year that can be treated as complete. Figures for 2025 and 2026 are still low, but that reflects publication lag of roughly 18 months rather than a real drop-off, so it is premature to call the field in decline based on the most recent two years alone. A fair read is that filing activity has cooled from its 2021 peak, with the post-2024 picture still forming.
Nearly all records (98.9%) sit under C12N, the core cell-culture and genetic engineering classification, which is expected given the search scope. Below that, C07K peptide and protein claims appear on 32.6% of records and A61K medicinal preparation claims on 30.4%, marking a therapeutic organoid branch. A23C dairy product claims (25.0%) and C12M bioreactor apparatus claims (20.7%) mark a separate cultured-food branch — the two together suggest metabolite-control techniques are being claimed both for drug development and for food production.
EP2764099A1, filed by Mitra RxDx India, claims an Extra Cellular Matrix composition specific to cancer type together with a tumor microenvironment platform for long-term culturing of tumor tissue. It also covers a Clinical Response Predictor used to select treatment options and a method for predicting a tumor patient's clinical response to specific drugs. Anyone building a diagnostic or drug-screening organoid platform that uses ECM composition tuned to tumor type should check this filing directly rather than assume it only covers basic culture technique.
The clearest gaps sit in sub-areas that appear thin relative to the core metabolite-control claim space: real-time redox-state sensing integrated into culture systems, ammonia scavenging designed for scaled bioreactors rather than bench-scale culture, and lactate control specifically for continuous-flow systems. These areas show up in the technology composition data as low-count adjacent classes (such as G01N test-method integration at 10.9% of records) rather than as a named competitor's stronghold, which makes them worth a targeted prior-art search before drafting.
Research Organoid Culture Metabolite Control in depth with Eureka
Go past this page: query the whole organoid culture metabolite control corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.